This patient should take fludrocortisone, not increase Solu-Cortef or adjust antihypertensives.
The blood pressure readings demonstrate classic orthostatic hypotension (standing BP 118/80 with HR 92 vs sitting/lying BP 141/81-79 with HR 66-73), indicating mineralocorticoid deficiency that requires fludrocortisone adjustment.
Clinical Reasoning
The orthostatic pattern is diagnostic:
- Standing BP drops by 23 mmHg systolic (141→118)
- Heart rate increases by 19-26 bpm when standing (compensatory tachycardia)
- This represents inadequate mineralocorticoid replacement, not glucocorticoid deficiency
Why fludrocortisone is the answer:
According to French consensus guidelines, monitoring and adjustment of mineralocorticoid replacement should be based on clinical signs of under-dosage including hypotension 1. The FDA label confirms fludrocortisone dosing ranges from 0.1-0.2 mg daily for primary adrenal insufficiency, with dose adjustments for transient hypotension 2.
The guidelines explicitly state that patients with primary adrenal insufficiency require mineralocorticoid replacement using fludrocortisone at a mean dose of 100 mcg/day (individually adjusted) 1. Clinical monitoring should identify signs of under-dosage such as hypotension 1.
Why NOT increase hydrocortisone:
The sitting/lying blood pressures are actually elevated (141/81-79), suggesting adequate or even excessive glucocorticoid replacement. Increasing hydrocortisone would worsen hypertension and is only indicated for acute illness, stress, or adrenal crisis 1. The patient shows no signs of acute adrenal insufficiency requiring stress-dose steroids.
Why NOT adjust antihypertensives:
This is not essential hypertension—it's positional hypotension from mineralocorticoid deficiency. The elevated sitting/lying pressures may actually reflect compensatory mechanisms for chronic volume depletion. Guidelines state that in hypertensive PAI patients, fludrocortisone dose reduction should be considered, but essential hypertension should be treated by adding vasodilators, not stopping mineralocorticoid replacement 3, 4. However, this patient's primary problem is orthostatic hypotension, not hypertension.
Management Algorithm:
Increase fludrocortisone dose (typically from 0.1 mg to 0.15-0.2 mg daily) 2
Ensure adequate salt intake (guidelines recommend free dietary sodium intake) 1
Monitor response with:
Reassess in 1-2 weeks and titrate fludrocortisone accordingly
Critical Pitfalls to Avoid:
- Don't mistake orthostatic hypotension for inadequate glucocorticoid replacement—the compensatory tachycardia and positional nature point to volume/mineralocorticoid issues
- Don't stop or reduce fludrocortisone because of elevated sitting BP—the orthostatic drop indicates under-replacement 3
- Don't use stress-dose hydrocortisone for chronic orthostatic symptoms—this is for acute illness only 1
- Glucocorticoid-induced adrenal insufficiency patients should NOT receive fludrocortisone 6, but this patient has primary adrenal insufficiency requiring both replacements
The evidence strongly supports that fludrocortisone under-replacement is common in clinical practice 7, and symptoms like postural dizziness persist in many treated PAI patients, suggesting chronic mineralocorticoid under-replacement is widespread.